Table 1.
Basic Characteristics of the Patients Who Underwent Redo SMVR and ViV TMVR (2015–2018)
| Variable | Unmatched | Propensity matched | ||||
|---|---|---|---|---|---|---|
| Redo SMVR, 2250 | ViV TMVR, 495 | P value | Redo SMVR, 395 | ViV TMVR, 395 | SMD | |
| Age, y, median (IQR) | 68 (60–75) | 77 (70–83) | <0.01 | 75 (67–81) | 74 (68–80) | −0.075 |
| Women, n (%) | 1150 (51.1) | 260 (52.5) | 0.57 | 220 (55.7) | 240 (60.8) | 0.101 |
| Race/ethnicity, n (%) | ||||||
| White | 1585 (74.9) | 360 (80.9) | <0.01 | 280 (70.9) | 285 (72.2) | … |
| Black | 185 (8.7) | 50 (11.2) | 40 (10.1) | 35 (8.9) | 0.046 | |
| Hispanic | 140 (6.6) | 15 (3.4) | 10 (2.5) | 15 (3.8) | −0.052 | |
|
Other (Asians, native Americans or missing race information) |
205 (9.6) | 20 (4.5) | 65 (16.4) | 60 (15.2) | 0.090 | |
| Comorbidities and medical history | ||||||
| Deficiency anemia, n (%) | 100 (4.4) | <11 (<2.0) | 0.01 | <11 (<2.8) | 15 (3.8) | 0.061 |
| Atrial fibrillation, n (%) | 1565 (69.6) | 305 (61.6) | <0.01 | 255 (64.6) | 240 (60.8) | −0.082 |
| Congestive heart failure, n (%) | 1445 (64.2) | 415 (83.8) | <0.01 | 320 (81.0) | 305 (77.2) | −0.079 |
| Chronic obstructive pulmonary disease, n (%) | 575 (25.6) | 140 (28.3) | 0.21 | 110 (27.8) | 115 (29.1) | 0.029 |
| Coagulopathy, n (%) | 975 (43.3) | 80 (16.2) | <0.01 | 75 (19.0) | 110 (27.8) | 0.178 |
| Coronary artery disease, n (%) | 950 (42.2) | 345 (69.7) | <0.01 | 250 (63.3) | 225 (57.0) | −0.128 |
| Cerebrovascular disease, n (%) | 185 (8.2) | 30 (6.1) | 0.12 | 25 (6.3) | <11 (<2.8) | −0.139 |
| Diabetes mellitus, n (%) | 185 (8.2) | 40 (8.1) | 0.92 | 40 (10.1) | 50 (12.7) | 0.094 |
| Hypertension, n (%) | 1705 (75.8) | 405 (81.8) | 0.004 | 320 (81.0) | 320 (81.0) | 0 |
| Liver disease, n (%) | 140 (6.2) | 30 (6.1) | 0.89 | 25 (6.3) | 45 (11.4) | 0.209 |
| Obesity, n (%) | 325 (14.4) | 55 (11.1) | 0.05 | 45 (11.4) | 60 (15.2) | 0.109 |
| Peripheral vascular disease, n (%) | 250 (11.1) | 90 (18.2) | <0.01 | 60 (15.2) | 70 (17.7) | 0.081 |
| Renal failure, n (%) | 670 (29.8) | 165 (33.3) | 0.12 | 125 (31.6) | 125 (31.6) | 0 |
| Smoking, n (%) | 165 (7.3) | 30 (6.1) | 0.32 | 30 (7.6) | 30 (7.6) | 0 |
| Charlson Comorbidity Index, median (IQR) | 5 (4–7) | 6 (5–8) | <0.01 | … | … | |
| Urban/rural, n (%) | ||||||
| Rural | <11 (<0.5) | <11 (<2.0) | 0.09 | … | <11 (<2.8) | … |
| Urban, nonteaching | 235 (10.4) | 40 (8.1) | 40 (10.1) | 20 (5.1) | −0.165 | |
| Urban, teaching | 2005 (89.1) | 455 (91.9) | 355 (89.9) | 365 (92.4) | 0.081 | |
| Hospital size, n (%) | ||||||
| Small | 195 (8.7) | 45 (9.1) | <0.01 | 45 (11.4) | 25 (6.3) | … |
| Medium | 455 (20.2) | 55 (11.1) | 50 (12.7) | 55 (13.9) | 0.032 | |
| Large | 1600 (71.1) | 395 (79.8) | 300 (75.9) | 315 (79.7) | 0.084 | |
| Primary payer, n (%) | ||||||
| Medicare | 1455 (64.7) | 395 (79.8) | <0.01 | 300 (75.9) | 320 (81.0) | … |
| Medicaid | 155 (6.9) | 20 (4.0) | 20 (5.1) | 20 (5.1) | 0 | |
| Private insurance | 575 (25.6) | 65 (13.1) | 65 (16.5) | 50 (12.7) | −0.087 | |
| Other | 65 (2.9) | 15 (3.0) | <11 (<2.8) | <11 (<2.8) | −0.078 | |
The <11 numbers are not reported per data‐provider recommendations.
IQR indicates interquartile range; SMD, standard mean difference; SMVR, surgical mitral valve replacement; and ViV TMVR, valve‐in‐valve transcatheter mitral valve replacement.